Arcutis Biotherapeutics, Inc.
ARQT
$26.23
$0.311.20%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 59.33% | 65.08% | 83.83% | 121.69% | 164.13% |
| Total Other Revenue | -- | -- | 0.00% | -- | -- |
| Total Revenue | 59.33% | 60.07% | 81.48% | 121.69% | 164.13% |
| Cost of Revenue | 46.01% | 10.80% | 69.27% | 57.82% | 116.28% |
| Gross Profit | 60.68% | 67.70% | 82.79% | 130.65% | 170.18% |
| SG&A Expenses | 18.75% | 15.74% | 37.10% | 6.10% | 18.90% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.02% | 26.68% | 40.67% | 8.20% | 18.76% |
| Operating Income | 212.44% | 62.95% | 340.92% | 121.82% | 70.82% |
| Income Before Tax | 197.43% | 54.80% | 270.71% | 118.03% | 70.30% |
| Income Tax Expenses | -60.23% | -66.67% | 45.51% | -- | -- |
| Earnings from Continuing Operations | 194.48% | 54.93% | 261.24% | 117.84% | 69.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 194.48% | 54.93% | 261.24% | 117.84% | 69.64% |
| EBIT | 212.44% | 62.95% | 340.92% | 121.82% | 70.82% |
| EBITDA | 220.96% | 60.43% | 358.92% | 124.05% | 71.94% |
| EPS Basic | 191.93% | 56.09% | 256.94% | 117.38% | 70.48% |
| Normalized Basic EPS | 194.77% | 55.98% | 266.22% | 117.57% | 71.12% |
| EPS Diluted | 184.62% | 56.09% | 243.09% | 117.38% | 69.33% |
| Normalized Diluted EPS | 191.11% | 55.98% | 257.06% | 116.85% | 71.12% |
| Average Basic Shares Outstanding | 2.78% | 2.64% | 2.67% | 2.67% | 2.85% |
| Average Diluted Shares Outstanding | 7.01% | 2.64% | 8.58% | 6.90% | 2.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |